Isoindolinone inhibitors of the MDM2-P53 interaction and process for making them
US11603367B2 · kind B2 · utility
2Cited by
17References
12Claims
0Family size
Assignees
Inventors
- Steven Howard
- Jeffrey David ST. DENIS
- Charlotte Mary Griffiths-Jones
- Steven Douglas Hiscock
- Alan Richard BURNS
- David Cousin
- Kim Louise Hirst
- James Daniel OSBORNE
- Jonas Calleja PRIEDE
- Aaron M. Dumas
- Brian Christopher Bishop
- David Parry-Jones
- Jeremy Scott
- Meenakshi Sundaram Shanmugham
- Peter Richard MULLENS
- Darren James DIXON
- Matthew James GAUNT
Key dates
| Filing date | Mar 28, 2018 |
| Grant date | Mar 14, 2023 |
| Priority date | — |
| Expiry date | Mar 28, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/13
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The invention relates to processes for preparing isoindolin-1-one derivatives, and in particular processes for preparing (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid. The invention also relates to crystalline forms of the compound (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid and its salts.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.